Diurnal Share Discussion Threads

[genierub] 10/1/2019 12:03

Here we go...

[amrishbhim] 10/1/2019 12:02

Read the RNS, this is not ramping these share, invest if you feel it's worth the news or not

[genierub] 10/1/2019 12:01

All dummy sells now incrementing. Get ready for the next wave :)

[genierub] 10/1/2019 12:00

As I said tree shake and nothing more. Get ready for the next leg up, the buyers are coming back. Try buying in any good volume right now - not happening. Far from over here.

[gersemi] 10/1/2019 11:58

Missed this rise :(

GLA...change in fortunes for the company and its suffering shareholders

[genierub] 10/1/2019 11:53

Amrish I will not lie, I do sense this has a very PYC feel to it and will motor after lunch (the lunchtime lull). The fact investors are still buying at these levels and the share price is well of its 52 week high is a positive for me.

Derampers will be out in full force but you only need to follow the money. Tree shake and then blast off again.

[amrishbhim] 10/1/2019 11:46

This will go past 1000% by next Wednesday, put my money into this, just an approval from FDA in USA worth that much or more that worth a billion plus in dollars, will have patents until 2033

[genierub] 10/1/2019 11:40

Is this one of those famous 600% style rises I have heard about in the past. Never seen one. Has to get past 100p for me to believe it can get back to year high of 200p. Watching with intent

[mikeh30] 10/1/2019 11:38

Billion pound market

[mikeh30] 10/1/2019 11:38

DEST billion £ market

[qs99] 10/1/2019 11:21

Thanks will take a look.

[bioking] 10/1/2019 11:10

OT) Please look at Futura Medical (FUM) has a dirt low market cap of 22 Million and 3 Drugs including a potential MEGA Blockbuster in Phase 3 trial which is light years better than Viarga and Cialis . If you look for a potential 10+ Bagger then load up FUM


Research Confirms MED2002's US$1 Billion Potential
hxxps://futuramedical.com/content/news/archive17/060317b.asp

The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time.

Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide.

Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life.

The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development.

The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action.

The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts.


Pipeline
hxxps://www.futuramedical.com/media/144144/Pipeline-2018.jpg

MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedical.com/content/products/med_2002.asp

first patient dosed: in Q3/Q4 2018
Last patient dosed: by end of June 2019
Headline efficacy results: by end of December 2019

CSD500: Erectogenic condom
hxxps://futuramedical.com/content/products/csd_500.asp

Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets.

Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedical.com/content/products/tpr_100.asp

TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018.
Out-licensing discussions for TPR100 outside of the UK are ongoing.

[qs99] 10/1/2019 11:02

did someone mention £2? Blimey this is motoring

[babbler] 10/1/2019 10:22

We expect by early 2019 that Alkindi(R) will be commercially available in the UK, Germany, Austria and the Nordic region. We also remain focused on completing pricing negotiations in key European territories as well as the finalisation of the clinical data package for Alkindi(R) in the US for submission to the FDA."

[babbler] 10/1/2019 10:14

could do I guess? quiet.

[colin12345678] 10/1/2019 09:43

Nice back to £2 then

[zen12] 08/10/2018 14:53

Derampers Cought Out by rns! “Prof Faisal Ahmed, Clinical Endocrinologist, University of Glasgow, added:

"We welcome this decision by the SMC. Administering a hydrocortisone dose titrated to children's needs is essential. Previously, licensed hydrocortisone was only available in adult dose sizes, making accurate dosing for children difficult. Alkindi® provides the ability to prescribe and administer small doses which is particularly important for young children. We look forward to finally using a preparation which is specifically designed for this group of patients."

[pugugly] 08/10/2018 13:58

So was the captain of the Titanic - at first !!

[zen12] 08/10/2018 12:22

There is still life in this and the BoD are defiant ‘We remain confident that Chronocort® will be a valuable treatment option for CAH patients.‘

[pugugly] 08/10/2018 11:48

"the primary objective of the trial was not met. " Hear this too often with pharma red hot hope start-ups - Usually end of road.

[uncleoswald] 22/9/2018 09:16

Very quiet here.
Profits struggling to get established!

[gersemi] 14/3/2018 08:50

Placing at 190p - £11m